European Regulators Find No Link Between GLP-1 Drugs and Suicidal Ideation

European Medicines Agency (EMA) investigations have concluded that GLP-1 class drugs, like Ozempic and Wegovy, used for weight loss and diabetes, do not cause suicidal thoughts or actions. This follows similar findings by the U.S. Food and Drug Administration (FDA). The EMA’s review, which began after anecdotal reports of self-harm thoughts in patients, involved an analysis of medical records, clinical trials, and a Nature Medicine study, showing lower risks of suicidal thoughts with GLP-1 drugs compared to other treatments. Despite these findings, the EMA and FDA continue to mandate ongoing monitoring for such events. This scrutiny comes as GLP-1 drugs have surged in popularity, but also amidst historical concerns related to psychiatric risks associated with previous obesity treatments.

To read more, click here.

[Source: STAT, April 12th, 2024]